Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Nem, Dieudonné ^a   Baranyai, Dorothea ^a   Qiu, Huan ^a   Gödtel Armbrust, Ute ^a   Nestler, Sebastian ^a   Wojnowski, Leszek ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR YY1; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; STEROID RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOCHROME P450 3A4 GENE; CYTOCHROME P450 3A5 GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; GENETIC VARIABILITY; HAPLORHINI; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE CELL; KIDNEY CELL CULTURE; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; TRANSGENIC MOUSE; XENOBIOTIC METABOLISM; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DOG; ENZYME INDUCTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYLOGENY; PHYSIOLOGY; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION;

MUS; PRIMATES;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DOGS; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PHYLOGENY; RECEPTORS, STEROID; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION; YY1 TRANSCRIPTION FACTOR;

EID: 84856079460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030895     Document Type: Article

References (68)

1. Ihunnah CA, Jiang M, Xie W, (2011) Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 1812: 956-963.
2. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, et al. (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279: 38379-38385.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP, (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.
4. Li HC, Dehal SS, Kupfer D, (1995) Induction of the hepatic CYP2B and CYP3A enzymes by the proestrogenic pesticide methoxychlor and by DDT in the rat. Effects on methoxychlor metabolism. J Biochem Toxicol 10: 51-61.
5. Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, et al. (1980) Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 27: 810-814.
6. Shah SC, Sharma RK, Hemangini, Chitle AR, (1981) Rifampicin induced osteomalacia. Tubercle 62: 207-209.
7. Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH, (2005) CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab 90: 1210-1219.
8. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH, (2004) CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res 19: 680-688.
9. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, et al. (2006) Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69: 56-65.
10. Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, et al. (2007) Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 28: 916-921.
11. Lash LH, Putt DA, Cai H, (2008) Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 244: 56-65.
12. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30: 1108-1114.
13. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, et al. (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50: 52-59.
14. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, et al. (2005) Association between the CYP3A5 genotype and blood pressure. Hypertension 45: 294-298.
15. Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, et al. (2005) The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 15: 831-837.
16. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, et al. (2005) Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol 20: 872-885.
17. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V, (2007) Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 22: 1963-1968.
18. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, et al. (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79: 1836-1842.
19. Matsuzaki K, Arai T, Miyazaki T, Yasuda K, (1995) Formation of 6 beta-OH-deoxycorticosterone from deoxycorticosterone by A6 cells. Steroids 60: 457-462.
20. Clore J, Schoolwerth A, Watlington CO, (1992) When is cortisol a mineralocorticoid? Kidney Int 42: 1297-1308.
21. Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP, (1998) A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 274: C1245-1252.
22. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11: 773-779.
23. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.
24. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, et al. (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34: 836-847.
25. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, et al. (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68: 1889-1902.
26. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, et al. (2005) Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos 33: 1074-1081.
27. Biggs JS, Wan J, Cutler NS, Hakkola J, Uusimaki P, et al. (2007) Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells. Mol Pharmacol 72: 514-525.
28. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102: 1016-1023.
29. Nishimura M, Naito S, Yokoi T, (2004) Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19: 135-149.
30. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, et al. (2004) PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199: 251-265.
31. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, et al. (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95: 12208-12213.
32. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82.
33. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, et al. (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12: 3195-3205.
34. Qiu H, Mathas M, Nestler S, Bengel C, Nem D, et al. (2010) The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics 20: 167-178.
35. Arthur JM, (2000) The MDCK cell line is made up of populations of cells with diverse resistive and transport properties. Tissue Cell 32: 446-450.
36. Verkoelen CF, van der Boom BG, Kok DJ, Houtsmuller AB, Visser P, et al. (1999) Cell type-specific acquired protection from crystal adherence by renal tubule cells in culture. Kidney Int 55: 1426-1433.
37. Iwano S, Saito T, Takahashi Y, Fujita K, Kamataki T, (2001) Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members. Biochem Biophys Res Commun 286: 55-60.
38. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, et al. (1993) Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218: 585-595.
39. Saito T, Takahashi Y, Hashimoto H, Kamataki T, (2001) Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. J Biol Chem 276: 38010-38022.
40. Hyde-DeRuyscher RP, Jennings E, Shenk T, (1995) DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res 23: 4457-4465.
41. Hariharan N, Kelley DE, Perry RP, (1991) Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc finger protein. Proc Natl Acad Sci U S A 88: 9799-9803.
42. Weill L, Shestakova E, Bonnefoy E, (2003) Transcription factor YY1 binds to the murine beta interferon promoter and regulates its transcriptional capacity with a dual activator/repressor role. J Virol 77: 2903-2914.
43. Shi Y, Lee JS, Galvin KM, (1997) Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta 1332: F49-66.
44. Cheng X, Klaassen CD, (2006) Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. Drug Metab Dispos 34: 1863-1867.
45. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101: 6062-6067.
46. Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H, Kudo T, (2001) The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol 172: 47-56.
47. Novotna A, Doricakova A, Vrzal R, Maurel P, Pavek P, et al. (2010) Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells. Eur J Pharm Sci 41: 276-280.
48. Luke MP, Sui G, Liu H, Shi Y, (2006) Yin Yang 1 physically interacts with Hoxa11 and represses Hoxa11-dependent transcription. J Biol Chem 281: 33226-33232.
49. Gordon S, Akopyan G, Garban H, Bonavida B, (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142.
50. Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H, (1999) Human prostate CYP3A5: identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun 260: 676-681.
51. Henshall J, Galetin A, Harrison A, Houston JB, (2008) Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications. Drug Metab Dispos 36: 1332-1340.
52. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, et al. (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62: 162-172.
53. Singer GA, Lloyd AT, Huminiecki LB, Wolfe KH, (2005) Clusters of co-expressed genes in mammalian genomes are conserved by natural selection. Mol Biol Evol 22: 767-775.
54. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, et al. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104: 147-153.
55. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, et al. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75: 1059-1069.
56. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, et al. (1976) Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12: 180-191.
57. Cedrone E, Reid Y, Eckard-Amar E, (2009) Tissue-culture adapted Influenza virus strains. ATCC Connection 29: 4-5, 15.
58. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. (2001) Natural protein variants of pregnane x receptor with altered transactivation activity toward cyp3a4. Drug Metab Dispos 29: 1454-1459.
59. Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L, (2007) Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch Pharmacol 375: 377-382.
60. Geick A, Eichelbaum M, Burk O, (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276: 14581-14587.
61. Qiu H, Taudien S, Herlyn H, Schmitz J, Zhou Y, et al. (2008) CYP3 phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7. Pharmacogenet Genomics 18: 53-66.
62. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, et al. (2008) NCBI BLAST: a better web interface. Nucleic Acids Res 36: W5-9.
63. Brudno M, Do CB, Cooper GM, Kim MF, Davydov E, et al. (2003) LAGAN and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res 13: 721-731.
64. Hall TA, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
65. Chekmenev DS, Haid C, Kel AE, (2005) P-Match: transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res 33: W432-437.
66. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, et al. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11: 111-121.
67. Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, et al. (2007) Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 35: 946-954.
68. Qiu H, (2008) Comparative genomics and phylogenetics of the vertebrate CYP3 family. Dissertation am Fachbereich Biologie der Johannes Gutenberg-Universität Mainz.